CynergisTek and Asimily Partner to Provide Complete Connected Device Lifecycle Management

Medical Device Investing

CynergisTek (NYSEA:CTEK) and Asimily have announced a partnership to provide joint security assessment for medical devices. As quoted in the press release: The joint offering will provide healthcare providers with the ability to identify all devices connected to the network and the relationship between those devices, the capability to discover any existing risks or anomalies …

CynergisTek (NYSEA:CTEK) and Asimily have announced a partnership to provide joint security assessment for medical devices.

As quoted in the press release:

The joint offering will provide healthcare providers with the ability to identify all devices connected to the network and the relationship between those devices, the capability to discover any existing risks or anomalies in the network, ability to discover and prioritize devices and vulnerabilities, and recommendations for mitigation and program improvement.

CynergisTek will use Asimily’s platform to provide risk assessment services as well as provide an ongoing managed service to its customers. During CynergisTek’s assessment, healthcare providers can trial Asimily’s solution with the option to purchase a license for continued device monitoring. Once licensed, Asimily’s solution will provide additional elements to providers for complete medical device lifecycle management, including detailed asset utilization, the ability to track and discover devices not being used as expected, and the capability to block or segment devices on the network. CynergisTek’s managed service will allow healthcare providers to identify and classify risks as well as determine appropriate technical remediation priorities on an ongoing basis. Together, CynergisTek and Asimily will help providers understand the number of biomedical devices connected to the network and the known risks and vulnerabilities to help customers develop a strategy to secure the devices going forward.

Click here to read the full press release.

The Conversation (0)
×